1096906-70-5Relevant academic research and scientific papers
Prodrug comprising a drug-linker conjugate
-
Paragraph 0234-0237, (2021/11/04)
The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group and wherein D-H is a polypeptide selected from the group of polypeptides consisting of exendins, glucagon, glucagon-like peptides and insulins. The invention also relates pharmaceutical composition comprising said prodrugs and their use as medicaments.
NOVEL HYDROGEL CONJUGATES
-
Page/Page column 149; 150, (2020/05/13)
The present invention relates to conjugates comprising backbone moieties that are crosslinked via particular crosslinker moieties to which a plurality of drug moieties are covalently and reversibly conjugated. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.
DEGRADABLE HYALURONIC ACID HYDROGELS
-
Page/Page column 290, (2020/05/13)
The present invention relates to conjugates comprising crosslinked hyaluronic acid to which a plurality of drug moieties are covalently and reversibly conjugated, wherein the hyaluronic acid exhibits a certain degree of modification and comprises degradable crosslinked moieties. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.
VEGF NEUTRALIZING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS
-
Page/Page column 136; 137, (2014/05/07)
The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
